EPO and anemia (phenotype): In light of this, we performed a retrospective cohort study in order to do a cost-effectiveness analysis from the payer perspective to estimate the potential impact of using two treatment strategies for anemia associated with CKD: short-acting erythropoietin: epoetin-beta three times weekly vs.